BULLET : Jurnal Multidisiplin Ilmu
Volume 1, No. 01, Maret (2022)
ISSN 2829-2049 (media online)
Hal 76-86

Implementation of artificial intelligence in biotechnology for rapid drug discovery and enabling personalized treatment through vaccines and therapeutic products

Anirudh Mehta

Independent Researcher, Norwood, Massachusetts USA

anirudhmehta158@gmail.com

Abstract: A new era of healthcare and biomedical research has been brought about by the merging of biotechnology with artificial intelligence (AI). This integration presents previously unheard-of prospects to expand scientific understanding, expedite medication discovery, and tailor therapies. In this study, we examine the ways in which biotechnology and artificial intelligence might work together to improve healthcare in a number of areas, such as individualized treatment plans, quick drug discovery, and the creation of therapeutic items. We go over how artificial intelligence (AI) algorithms use massive amounts of biological and chemical data to forecast medication success, optimize treatment plans, and speed up the search for new treatments. We also look at how biotechnology can be used to translate AI-driven predictions into interventions that are applicable to clinical settings, such as the creation of customized vaccinations, gene therapies, and products for regenerative medicine. We draw attention to the difficulties and constraints that come with integrating biotechnology and AI in healthcare, such as the complexity and interpretability of the data, ethical issues, legal barriers, and societal ramifications. Lastly, we talk about the potential applications of biotechnology and AI in healthcare going forward, such as the creation of more understandable AI algorithms, the fusion of systems biology and multi-omics data, and the development of customized medical devices and regenerative medicine treatments. We can fully utilize biotechnology and AI to change healthcare delivery, enhance patient outcomes, and influence the course of medicine by tackling these issues and embracing these new approaches.

Key words: Biotechnology, healthcare, personalized medicine, drug discovery, high-throughput screening, machine learning, ethics, interpretability, multi-omics data, systems biology, medical devices, diagnostics, nanotechnology, tissue engineering, genomics, proteomics, regenerative medicine, high-throughput screening.

INTRODUCTION

The field of drug development and customized medicine has seen a significant transformation in recent years due to the combination of biotechnology and artificial intelligence (AI). This integration has created new opportunities for the development of medicines and vaccines by opening doors for creative solutions to difficult healthcare problems. The conventional drug development method is frequently characterized by high failure rates, resource requirements, and length of time [1]. But the development of AI technologies has fundamentally changed how scientists find possible drug candidates, assess their efficacy, and tailor treatment plans. Researchers may sort through enormous volumes of biological and chemical data by using artificial intelligence (AI) through leveraging machine learning algorithms and big data analytics. This allows researchers to find hidden patterns and associations that could be the key to developing novel therapeutic products.

Conversely, biotechnology comprises an extensive array of methods and approaches that utilize biological systems to create novel medications, diagnostic tools, and vaccinations. The creation of biologics—complex compounds produced from live organisms—has been made possible by biotechnological techniques including genetic engineering, recombinant DNA technology, and protein engineering [2]. These molecules are now essential to modern medicine. AI and biotechnology together provide a potent toolkit for speeding up the drug discovery process. Through the integration of biological assays, high-throughput screening, and computer modeling, researchers can more precisely and effectively identify viable drug candidates. AI-driven platforms can also forecast the safety and efficacy profiles of possible treatments, which lowers the possibility of side effects and improves patient outcomes [3].

Artificial intelligence (AI) and biotechnology are propelling the creation of tailored therapeutic approaches while also expediting the medication discovery process. The goal of personalized medicine is to customize treatment plans for individual patients according to their distinct genetic composition, lifestyle choices, and illness features. Healthcare professionals can stratify patients into subpopulations with distinct treatment responses by utilizing AI algorithms and genomic profiling approaches. This allows for more focused and efficient therapy. Moreover, the swift progress of artificial intelligence and biotechnology has stimulated creativity in the creation of vaccines. Agile vaccination systems are desperately needed because of the rise in infectious diseases and the continuous threat of pandemics [4]. These platforms must be able to react rapidly to emerging pathogens. In order to facilitate the quick creation of preventive vaccinations against new disease risks, AI-enabled vaccine design tools can expedite the discovery of antigenic targets, optimize vaccine formulations, and predict immune responses.

BULLET : Jurnal Multidisiplin Ilmu
Volume 1, No. 01, Maret (2022)
ISSN 2829-2049 (media online)
Hal 76-86

AN OVERVIEW OF DRUG DISCOVERY USING ARTIFICIAL INTELLIGENCE

In the field of drug discovery, artificial intelligence (AI) has become a game-changing technology that offers creative ways to speed up the discovery and development of novel therapies. AI allows researchers to quickly identify new drugs and gain significant insights from copious amounts of chemical and biological data by applying machine learning algorithms, deep learning techniques, and big data analytics. Finding possible treatment candidates with great efficacy and few adverse effects is one of the main challenges in drug discovery. Large libraries of chemical compounds are typically screened against therapeutic targets as part of this process, which is resource- and time-intensive [5]. But thanks to AI-driven methods, compound libraries can now be virtually screened using predictive models that have been trained on a variety of datasets. This has completely changed the process.

Because machine learning methods use chemical structure to predict biological activity, they are essential to virtual screening. These algorithms are able to find new compounds with comparable pharmacological characteristics by learning from the available data on established drug-target interactions. AI models can considerably cut down on the time and expense involved with conventional screening techniques by prioritizing lead compounds for additional experimental validation by examining the structural characteristics of active compounds and their interactions with target proteins [6]. AI is being used not just for virtual screening but also for drug candidate optimization and pharmacokinetic and pharmacodynamics property prediction. Artificial intelligence (AI) algorithms can create prediction models of drug action in the human body by combining data from various sources, such as clinical, proteomic, and genomic databases. These models can assist researchers in predicting side effects, finding possible drug-drug interactions, and fine-tuning dosage schedules to enhance therapeutic efficacy [7].

AI-driven methods are also revolutionizing the process of drug repurposing, which involves assessing current medications for potential new therapeutic uses. AI systems are able to rank prospective medications for experimental validation and discover possible drug-disease connections by examining large-scale omics data and biomedical literature. By utilizing already-existing medicinal molecules with proven safety profiles, this helps researchers to discover new treatments for a variety of ailments more quickly. Drug discovery is also making greater use of deep learning methods like recurrent neural networks (RNNs) and convolutional neural networks (CNNs) [8]. These algorithms are particularly good at deciphering significant patterns and relationships from complicated, high-dimensional data, such biological sequences and chemical structures. For instance, RNNs can simulate temporal correlations in biological data, such as gene expression profiles, while CNNs can be used to predict protein-ligand binding affinity based on three-dimensional structure information [9].

All things considered, the application of artificial intelligence to drug discovery has great potential to speed up the creation of new medicines and meet unmet medical requirements Researchers can enhance drug candidates, find hidden insights in biological data, and accelerate the transition of fundamental research into clinical applications by utilizing machine learning, deep learning, and big data analytics. AI technologies have the potential to completely transform the pharmaceutical sector and bring in a new era of individualized medicine as they develop further [10].

BIOTECHNOLOGY INTEGRATION IN DRUG DEVELOPMENT

Today, biotechnology is a key component of medication research because it provides effective methods and instruments for finding, creating, and developing new treatments. In order to produce pharmaceutical chemicals, biotechnological methods alter living creatures or biological systems using the concepts of biology, genetics, and molecular biology. The creation of biologics—complex compounds originating from living organisms—as a result of this integration has revolutionized the way that many diseases are treated. The capacity of biotechnology to create biologics with great specificity and potency is one of its main advantages in the drug development process [11]. In contrast to conventional small molecule medications, which are chemically synthesized, biologics are usually made by protein engineering or recombinant DNA technologies. This makes it possible for scientists to precisely design therapeutic proteins, antibodies, and nucleic acids to target certain biological targets or disease pathways, leading to more specialized and effective treatments.

The use of recombinant DNA technology, which modifies DNA molecules to produce unique genetic constructions, has completely changed how biologics are produced. Researchers can use the cellular machinery of host species like bacteria, yeast, or mammalian cells to manufacture huge amounts of recombinant proteins by

Volume 1, No. 01, Maret (2022)
ISSN 2829-2049 (media online)
Hal 76-86

adding genes encoding therapeutic proteins into those organisms [12]. This has made it possible to produce a range of biologic medications, including monoclonal antibodies, growth factors, cytokines, and insulin, on a commercial scale. These therapies are now vital treatments for a number of illnesses. To improve the stability and effectiveness of therapeutic proteins, protein engineering techniques are also commonly utilized in biotechnology alongside recombinant DNA technology. Researchers can alter the amino acid sequence of proteins to enhance its pharmacokinetic, specificity, and binding affinity using methods like directed evolution or rational design. This makes it possible to create biologics of the next generation with improved therapeutic characteristics, like stronger effects, lowered immunogenicity, and longer half-lives in circulation [13].

Additionally, biotechnology is essential to the development of gene and cell-based therapies, which have great potential in treating cancer, genetic abnormalities, and other diseases for which there is a lack of effective treatment. While cell treatment includes transplanting genetically modified cells to restore tissue function or boost immune responses, gene therapy involves delivering therapeutic genes into target cells to fix genetic abnormalities or modify disease pathways [14]. The treatment of genetic illnesses may now be approached more creatively because of developments in gene editing technologies like CRISPR-Cas9.

These technologies have made targeted gene delivery and precise genome editing possible. Proteomics, metabolomics, and synthetic biology are just a few of the many different methods and techniques that fall under the broad category of biotechnology and are useful in the drug development process. The identification and characterization of protein targets implicated in disease pathways is made possible by proteomics techniques, which offer important new information for the development of new drugs. Researchers can more easily identify biomarkers and potential therapeutic targets by profiling small molecule metabolites in biological samples using metabolomics methods. Through the use of synthetic biology approaches, biological systems can be engineered to generate new substances or optimize metabolic pathways for medical applications [15].

The integration of biotechnology into drug research has sparked a revolution in the pharmaceutical industry.. This has made it possible to produce cell-based therapies, gene therapies, and biologics, which provide novel treatment options for a variety of disorders. By utilizing biotechnological techniques such as gene editing, protein engineering, and recombinant DNA technology, scientists can develop and manufacture medications with improved safety, potency, and specificity [16]. With biotechnology's continued advancement, customized medicine and medication development will likely see even more innovation, leading to the emergence of precision medicines catered to the specific needs of each patient.

QUICK DRUG FINDING METHODS

Finding viable drug candidates promptly and effectively is essential in the fast-paced field of drug discovery in order to fill medical gaps and provide patients new treatments. Utilizing cutting-edge methodologies, sophisticated technologies, and high-throughput screening techniques, rapid drug discovery strategies expedite the identification and optimization of possible therapies. Using in silico screening methods and computer modeling is one of the main approaches for speeding up the drug discovery process. By using computational techniques like molecular docking, molecular dynamics simulations, and quantitative structure-activity relationship (QSAR) modeling, scientists can forecast how tiny molecules will attach to target proteins and behave biologically. Researchers can find lead compounds with possible therapeutic efficacy by screening virtual libraries of chemical compounds against molecular targets of interest [17]. This process reduces the requirement for laborious experimental screening.

High-throughput screening (HTS) is an additional potent method for expediting drug discovery as shown in figure.

BULLET : Jurnal Multidisiplin Ilmu
Volume 1, No. 01, Maret (2022)
ISSN 2829-2049 (media online)
Hal 76-86



Figure 1: Steps involved in the process of drug discovery [17]. (As MDPI is an open source so picture is resued and reference is given here***)***

With HTS, chemical compounds with desired pharmacological activity can be quickly identified by researchers by use of parallel, automated testing of huge libraries of compounds against biological targets. This method greatly speeds up the drug development process by allowing thousands to millions of compounds to be screened in a short amount of time. Moreover, developments in assay technology, robotics, and liquid handling systems have improved the efficiency and throughput of HTS platforms [18]. Another method for accelerating the search for new drugs is combinatorial chemistry, which creates vast libraries of various chemical compounds for screening. Combinatorial chemistry techniques combine building blocks or chemical reactions in a systematic way to synthesize a large number of structurally varied molecules. Then, by screening these chemical libraries against biological targets, lead compounds with the appropriate characteristics can be found. Small molecule drug development has benefited greatly from combinatorial chemistry, which has given researchers access to a vast Recent development in microfluidics technology have allowed for the automation and downsizing of experimental tests, completely changing the drug discovery landscape [19].

By using highly parallel and efficient techniques, microfluidic devices enable researchers to carry out intricate biochemical and cellular experiments with less reagent usage, sample quantities, and experimental time. Microfluidic platforms offer unparalleled capabilities for quick and economical experimentation and can be applied to a wide range of drug discovery applications, such as biomarker detection, drug screening, and cell-based assays. Additionally, developments in high-content screening (HCS) have made it possible for scientists to assess possible treatments' effects at the cellular and subcellular levels of intricate biological systems [20]. Automated microscopy, image analysis, and data visualization methods are combined in HCS to obtain comprehensive data regarding drug responses and cellular phenotypes. Researchers may detect minute changes in cellular shape, function, and signaling pathways in response to medication treatments by using HCS, which analyzes dozens of biological characteristics simultaneously. This information is particularly helpful for drug development and discovery [21].

Utilized by rapid drug discovery strategies to expedite the identification and refinement of possible treatments. Combinatorial chemistry, high-throughput screening, microfluidics, in silico modeling, and high-content screening techniques can help speed up the drug development process, lower the time and expense of introducing new medications to the market, and ultimately improve patient outcomes. These methods have the potential to completely change the drug discovery industry and usher in a new era of precision medicine as they develop and become more advanced [22].

BULLET : Jurnal Multidisiplin Ilmu
Volume 1, No. 01, Maret (2022)
ISSN 2829-2049 (media online)
Hal 76-86

PERSONALIZED METHODS OF CARE

Precision medicine, another name for personalized medicine, is a paradigm change in healthcare that seeks to customize medical interventions to the unique needs of each patient. This method acknowledges that a person's response to a treatment may vary depending on their genetic composition, lifestyle choices, external variables, and illness features. Utilizing cutting-edge technologies like proteomics, genetics, and bioinformatics, personalized treatment approaches can identify patient subgroups with unique reactions to treatment and create tailored medications that maximize benefits and reduce side effects [23]. Genomic analysis, which looks at a person's genetic makeup to find genetic differences that may affect a disease's susceptibility, course, and response to treatment, is one of the main tenets of customized treatment techniques.

The rapid and affordable sequencing of complete genomes, exomes, and transcriptomes has been made possible by advancements in next-generation sequencing (NGS) technologies, offering previously unheard-of insights into the genetic causes of disease. Researchers can find genetic indicators linked to treatment response and disease outcomes by studying genetic variants, such as copy number variations (CNVs) and single nucleotide polymorphisms (SNPs). This allows for the development of targeted therapeutics that are customized for specific patients [24].

Within the specialty area of personalized medicine known as pharmacogenomics, the investigation of how a person's genetic makeup influences how they react to medications is the main focus. By analyzing genetic markers that affect drug metabolism, pharmacokinetics, and pharmacodynamics, pharmacogenomics testing enables medical professionals to forecast a patient's propensity to respond to a specific medication and modify treatment plans appropriately [25]. Genetic differences in drug-metabolizing enzymes, such as cytochrome P450 enzymes, can impact the effectiveness and metabolism of specific pharmaceuticals, resulting in differences in the way the drug reacts to the body and possible side effects. Healthcare professionals can optimize drug selection, dosing, and monitoring to enhance therapeutic efficacy and reduce the likelihood of adverse drug reactions by incorporating pharmacogenomics information into clinical decision-making.

Personalized therapy techniques utilize not just genomics but also other omits technologies, including proteomics, metabolomics, and macrobiotics, to analyze each patient's unique biological profile and customize therapeutic actions. Proteomics approaches facilitate the discovery and measurement of proteins and biomarkers linked to disease states, offering significant insights into the mechanisms underlying disease and possible targets for therapeutic intervention. By profiling small molecule metabolites in biological samples, researchers can gain insights into metabolic pathways that are deregulated in disease and uncover biomarkers for prognosis and diagnosis. This is made possible by the application of metabolomics techniques [26]. The study of the human micro biome, or the group of bacteria that live in the human body, and its significance for both health and illness is the main focus of macrobiotics. Researchers can discover microbial signatures linked to disease states and create micro biome-based therapeutics to alter microbial communities and improve health by examining the structure and function of the micro biome.

By evaluating complicated omits data and clinical information to forecast treatment outcomes and optimize therapeutic actions, machine learning and artificial intelligence (AI) are also becoming more and more significant components of individualized therapy approaches. To create predictive models of illness development and treatment response, artificial intelligence (AI) algorithms can integrate data from a variety of sources, including genomes, proteomics, metabolomics, electronic health records, and medical imaging. These models can assist medical professionals in determining the best course of action for each patient, projecting the possibility of treatment success or failure, and customizing interventions according to the preferences and features of the individual patient [27].

Individualized treatment plans attempt to adjust medical interventions to the unique qualities of every patient, marking a paradigm shift in the field of healthcare. Through the utilization of cutting-edge technologies, including macrobiotics, proteomics, metabolomics, pharmacogenomics, genomics, and artificial intelligence, researchers and healthcare professionals can identify patient subgroups with unique responses to treatment and create customized treatments that maximize benefits and reduce side effects [28]. Personalized medicine has the potential to transform healthcare delivery, enhance patient outcomes, and open the door to more accurate and potent therapies for a variety of diseases as it develops and becomes more incorporated into clinical practice.

BULLET : Jurnal Multidisiplin Ilmu
Volume 1, No. 01, Maret (2022)
ISSN 2829-2049 (media online)
Hal 76-86

VACCINES' PLACE IN PERSONALIZED MEDICINE

Because they offer targeted protection against infectious diseases depending on individual variables, such as age, health condition, immune response, and genetic factors, vaccines are essential to personalized medicine. Although vaccinations were once thought of as one-size-fits-all treatments, developments in immunogenomics and vaccine technology have made it possible to create individualized vaccinations that are suited to a patient's immune profile, risk of disease, and therapeutic need. The application of synthetic biology and recombinant DNA technologies to the design and production of vaccines with improved safety and efficacy profiles is one of the major developments in personalized vaccinations [29]. Conventional vaccinations generally use inactivated or live-attenuated microorganisms, which may increase the risk of allergic reactions or insufficient immune responses in some populations, such as elderly or immunocompromised people. Recombinant DNA technology, on the other hand, enables scientists to create vaccines that express particular pathogen epitopes or antigenic proteins, eliciting tailored immune responses without raising the risk of illness or infection [30].

In order to customize vaccine formulations to each individual's immunological profile and genetic background, personalized vaccine techniques also make use of immunogenomics knowledge. In order to find genetic markers linked to vaccination efficacy, immunogenicity, and adverse effects, immunogenomic studies seek to define the genetic differences that impact immune responses to vaccines and infectious illnesses. Researchers can tailor vaccination formulations to maximize immune responses and reduce side effects by adding genetic information into vaccine design and development. This approach leads to more effective and safer immunizations for individual patients [31].

Moreover, a variety of vaccination modalities, such as mRNA, viral vector, DNA, and recombinant protein vaccines, which provide unique benefits in terms of safety, immunogenicity, and scalability, are included in personalized vaccine techniques. For example, mRNA vaccines have shown promise in accelerating the development of vaccines against infectious diseases, such as COVID-19, by providing genetic instructions to cells that direct them to generate particular antigenic proteins and elicit immune responses. In order to stimulate immune responses against target pathogens, attenuated viruses are used in viral vector vaccines as delivery systems to introduce antigenic proteins or DNA sequences into cells [32]. Without the use of adjuvants or live viruses, DNA vaccines allow the generation of particular immune responses by directly delivering plasmid DNA encoding antigenic proteins into cells. Recombinant protein vaccines provide exact control over antigen composition and immunogenicity by stimulating immune responses with pure proteins or peptides obtained from infections.

Beyond infectious disorders, therapeutic vaccines for cancer, autoimmune diseases, and other chronic conditions are also included in the category of personalized vaccine approaches. Therapeutic vaccinations are intended to be used as potential treatments for a variety of diseases by utilizing the immune system to target and destroy sick cells or modify abnormal immune responses. For example, cancer vaccines boost the immune system's ability to identify and eliminate cancer cells by triggering reactions against antigens or neoantigens unique to tumors [33]. Vaccines against autoimmune diseases aim to suppress aberrant immune responses and rebuild immunological tolerance by targeting self-antigens or immune checkpoints.

These vaccines may be used to treat autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis. Vaccinations are essential to customized medicine since they offer tailored protection against infectious diseases as well as possible cures for autoimmune diseases, cancer, and other chronic illnesses. Researchers can create individualized vaccinations that are suited to each patient's immune profile, risk of disease, and treatment need by utilizing developments in immunogenomics, synthetic biology, and vaccine technology. Personalized vaccination techniques have the potential to transform healthcare delivery, enhance patient outcomes, and progress precision medicine as they develop and become more incorporated into clinical practice [34].

MEDICINAL ITEMS IN CUSTOMIZED CARE

At the vanguard of personalized therapy are therapeutic solutions that are customized for each patient. These products offer focused interventions that take into account the distinctive qualities of each individual, such as genetic makeup, illness phenotype, and response to treatment. Small molecule medications, biologics, gene therapies, cell-based therapies, and products from regenerative medicine are just a few of the many modalities that make up these customized therapeutics. All of these treatments are intended to target certain disease pathways and improve patient outcomes [35].

One of the most popular therapeutic methods in personalized medicine is the use of small molecule medications, which provide focused therapies for a variety of diseases, such as cancer, infectious diseases, autoimmune disorders, and metabolic abnormalities. Small molecule medications modify biological pathways implicated in the pathophysiology of disease by interacting with certain molecular targets, such as enzymes, receptors, or ion channels. Small molecule medications can give accurate, efficient treatments that are individualized for each patient by focusing on important molecules that are involved in the progression of the illness [36].

With their high specificity and effectiveness, biologics—such as recombinant proteins, monoclonal antibodies, and nucleic acid-based therapeutics—have completely changed the way that many diseases are treated. Utilizing cutting-edge biotechnology methods like protein engineering and recombinant DNA technologies, biologics are created to create therapeutic molecules with exact structural and functional characteristics [37]. These compounds provide tailored treatments that reduce off-target effects and optimize therapeutic efficacy by focusing on particular disease pathways or biological targets.

Gene treatments are a potentially effective means of providing individualized care as they can rectify genetic flaws, alter disease processes, and bring back regular cellular function. In order to replace or enhance damaged genes, produce functional proteins, or alter gene expression to treat or prevent disease, gene therapy entails delivering therapeutic genes into target cells. Thanks to developments in gene editing technologies like CRISPR-Cas9, targeted gene delivery and precise genome editing are now possible, opening up previously unheard-of possibilities for customized treatments based on each patient's unique genetic profile [38].

Cell-based treatments use immune or stem cells' capacity for regeneration to heal injured tissues, control immunological responses, and rebuild sick organs. Numerous illnesses, such as autoimmune diseases, neurological problems, and cardiovascular diseases, can be treated individually using these therapies. While immune cell therapies use immune cells like T cells or dendritic cells to target and eliminate diseased cells or modulate immune responses, stem cell therapies use transplanting stem cells into damaged tissues to promote tissue repair and regeneration. Products used in regenerative medicine comprise a wide range of therapeutic modalities intended to promote tissue regeneration, restore tissue function, and repair damaged organs [39]. These goods, which aid in tissue regeneration and repair in vivo, include cell-based therapies, biomaterials, and tissue-engineered constructions. Researchers can create customized regenerative medicine products that are suited to the specific needs of each patient by utilizing advancements in tissue engineering, biomaterials science, and cell biology. These products have the potential to treat a variety of illnesses and injuries.

To sum up, personalized treatment with therapeutic items offers focused interventions that take into account the distinct qualities of every person, such as genetic composition, illness phenotype, and response to treatment. Utilizing developments in gene therapies, cell-based therapies, biologics, small molecule pharmaceuticals, and regenerative medicine products, researchers and healthcare professionals can create customized treatments that maximize therapeutic results and enhance patient quality of life. Personalized treatment techniques have the potential to completely change the way healthcare is delivered, improve patient care, and progress precision medicine as they develop further and are incorporated into clinical practice [40].

BIOTECHNOLOGY AND ARTIFICIAL INTELLIGENCE IN HARMONY

A potent synergy between biotechnology and artificial intelligence (AI) is transforming drug discovery, personalized treatment, and biomedical research, among other areas of healthcare. By combining the advantages of the two disciplines, this convergence improves data analysis, predictive modeling, and experimental design, ultimately quickening the rate of scientific advancement and enhancing patient outcomes. Drug discovery is one of the main areas where biotechnology and AI interact. Large volumes of biological and chemical data can be analyzed by AI algorithms to find promising drug candidates, forecast their efficacy, and customize treatment plans [41].

Researchers can find hidden patterns and links in biological data by combining computational modeling, machine learning, and big data analytics. This can help discover new therapeutic approaches. Conversely, biotechnology offers the experimental instruments and techniques required to verify AI-generated forecasts and refine medication candidates for therapeutic application [42]. Combining AI and biotechnology allows for a more methodical and effective approach to drug discovery, which cuts down on the time and expense involved in introducing new medications to the market.

AI and biotechnology are advancing personalized medicine by enabling the creation of individualized medicines based on the unique characteristics of each patient. Healthcare providers can personalize treatment regimens by using AI algorithms that assess clinical, proteomic, and genetic data to stratify patients into subpopulations with different treatment responses. Gene therapies, cell-based therapies, and targeted biologics are examples of customized medications that can be developed using biotechnology to meet the unique needs of individual patients.

Personalized medicine can improve patient outcomes and lower the risk of adverse responses by delivering more accurate and effective therapies by fusing biotechnological advancements with AI-driven insights [43].

By facilitating more effective experimentation and data analysis, biotechnology and AI are revolutionizing biomedical research. Gene expression profiles, protein interactions, and cellular pathways are examples of complicated biological data that AI systems can examine to provide new insights into disease causes and possible treatment targets. High-throughput screening assays, genome editing instruments, and single-cell analysis methods are examples of experimental platforms offered by biotechnology that produce vast amounts of biological data suitable for AI analysis. Scientists can create novel answers to challenging biomedical problems and quicken the speed of discovery by fusing biotechnological testing with AI-driven hypothesis development [44].

AI and biotechnology are expediting the process of finding and improving therapeutic candidates in the drug development process. Drug candidates' pharmacokinetic and pharmacodynamic characteristics can be predicted by AI algorithms, allowing researchers to rank the compounds that have the best chance of being successful. Protein engineering, recombinant DNA technology, and high-throughput screening assays are examples of experimental methods provided by biotechnology that facilitate the quick development and evaluation of possible treatments. It is possible for researchers to identify lead compounds more quickly and move them through the drug development pipeline by combining biotechnological testing with AI-driven predictions [45].

Biotechnology and AI are enabling the creation of cutting-edge diagnostic and medicinal technologies. AI systems can help in disease diagnosis, prognosis, and treatment planning by analyzing genomic sequences, medical imaging data, and patient health records. Biotechnology offers the tools to create cutting-edge medical devices that use AI-driven insights to enhance patient care, such as biosensors, implantable devices, and point-of-care diagnostics. Researchers can create next-generation medical devices and diagnostics that allow for earlier detection, more accurate diagnosis, and more individualized treatment plans by fusing biotechnological innovation with AI-driven analysis [46].

OBSTACLES AND RESTRICTIONS

The intricacy and diversity of biological systems present one of the main obstacles to the successful integration of biotechnology with artificial intelligence. The biological data is inherently variable, noisy, and incomplete, which makes it challenging to derive significant predictions and insights. These obstacles must be overcome by AI algorithms in order to yield accurate and trustworthy results, necessitating the use of complex feature selection, data preparation, and model validation strategies. Moreover, intricate interactions take place at several dimensions in biological systems, ranging from molecular pathways to physiological systems, making them extremely interconnected and dynamic. To produce reliable predictions and suggestions, AI models must therefore be able to capture these dynamic interactions and adjust to changes in the biological setting [47].

The transparency and interpretability of AI algorithms in the healthcare industry present another difficulty. Deep learning algorithms in particular are frequently referred to as "black boxes" because of their intricate, non-linear design, which makes it challenging to comprehend how they generate their predictions or suggestions. Interpretability and transparency are essential for fostering trust and guaranteeing responsibility in the healthcare industry, where choices can have far-reaching effects. To help AI-driven predictions become more widely used in therapeutic settings, researchers and practitioners must therefore create means of interpreting and verifying these predictions [48].

The ethical issues of consent, privacy, and data ownership also present serious obstacles to the application of biotechnology and AI in healthcare. Concerns with data security, patient privacy, and informed permission are raised by the extremely sensitive and private nature of biomedical data, which includes genetic sequences, medical pictures, and electronic health records. If AI algorithms are not thoroughly constructed and evaluated, they may unintentionally divulge sensitive information or reinforce biases. These algorithms are trained on large-scale biological datasets. In addition, there are still unanswered concerns about data ownership and governance, especially when it comes to data sharing and cooperation between public and commercial organizations, academic institutions, and healthcare providers. Clear policies, rules, and governance structures are needed to address these ethical issues and guarantee that AI-driven medical technology is applied morally and responsibly [49].

The amalgamation of biotechnology with artificial intelligence has immense potential to revolutionize healthcare and biomedical research; nevertheless, it also poses some obstacles and constraints that necessitate attention. To address technical issues with data complexity, interpretability, and transparency, novel strategies and techniques are needed. Ethical concerns about consent, privacy, and data ownership demand that governance frameworks, policies, and guidelines be very clear. It is imperative to tackle regulatory and legal obstacles in order to guarantee patient safety and preserve public confidence in healthcare. A holistic approach that takes into account the social, economic, and cultural aspects that influence healthcare access and utilization is necessary to address societal concerns, such as discrepancies in healthcare access and the use of digital technology. Through responsible and cooperative approaches to these problems, we can fully utilize biotechnology and artificial intelligence to enhance patient outcomes, expand scientific understanding, and revolutionize healthcare delivery [50].

PROSPECTIVE COURSES

Though the road is far from done, the combination of biotechnology and artificial intelligence (AI) has already significantly transformed healthcare and biomedical research. The future of AI and biotechnology in healthcare will be excitingly shaped by new opportunities and problems that arise as technology continues to progress and our understanding of biological systems expands. The creation of increasingly sophisticated and comprehensible AI algorithms is one of the main future paths for biotechnology and AI in healthcare. Even while deep learning has demonstrated great promise in interpreting complicated biological data and producing precise predictions, its interpretability issues continue to be a major roadblock to its broad use in clinical practice [51]. In order to give healthcare professionals confidence in and comprehension of AI-driven recommendations, future research endeavors will concentrate on creating AI algorithms that are not only more reliable and accurate but also more transparent and comprehensible.

The advancement of customized medicine will be greatly aided by the integration of systems biology techniques and multi-omics data. Researchers will use multi-omits data, such as genomics, transcriptomics, proteomics, metabolomics, and macrobiotics, more and more to define disease states and find new therapeutic targets as our understanding of the molecular mechanisms behind disease expands. Researchers will be able to create comprehensive illness models that reflect the dynamic structure of biological systems and guide individualized treatment plans thanks to systems biology techniques, which simulate the intricate connections between biological components and pathways [52]. AI and biotechnology will continue to spur innovation in drug research by facilitating the creation of more effective and efficient drug discovery pipelines.

AI algorithms will be utilized more and more to find innovative drug combinations, optimize drug formulations, and forecast the pharmacokinetic and pharmacodynamics features of drug candidates. The experimental tools and procedures required to test AI-driven predictions and convert them into clinically applicable medicines will be made available by biotechnology. More physiologically appropriate models for drug testing will be possible thanks to developments in organ-on-a-chip technology, 3D bio printing, and high-throughput screening techniques. This will lessen the need for animal models and speed up the drug development process [53].

The combination of biotechnology and AI will result in the creation of more accurate and customized medical tests and technologies. AI systems will examine genomic sequences, electronic health records, and medical imaging data to help with illness diagnosis, prognosis, and treatment planning. Biotechnology will make it possible to create cutting-edge medical gadgets that use AI-driven insights to enhance patient care, such as wearable technology, biosensors, and point-of-care diagnostics. Developments in bioinformatics, microfluidics, and nanotechnology will make it possible to create portable, miniature devices for remote monitoring, point-of-care diagnostics, and customized treatment delivery [54].

REFERENCES

1. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles. Br J Pharmacol. 2011; 162(6):1239-49. doi: 10.1111/j.1476-5381.2010.01127.x, PMID 21091654.
2. Drug development: the journey of a medicine from lab to shelf [Home page on internet] [cited Jun 25 2021]. Available from: https://pharmaceutical-journal.com/article/feature/drug-development-the-journey-of-a-medicine-from-lab-to-shelf.
3. Van Gool, A. J.; Bietrix, F.; Caldenhoven, E.; et al. Bridging the Translational Innovation Gap through Good Biomarker Practice. Nat. Rev. Drug Discov. 2017, 16, 587.
4. Kraus, V. B. Biomarkers as Drug Development Tools: Discovery, Validation, Qualification and Use. Nat. Rev. Rheumatol. 2018, 14, 354–362.
5. West, H. J. Novel Precision Medicine Trial Designs: Umbrellas and Baskets. JAMA Oncol. 2017, 3, 423–423.
6. The Latest on Drug Failure and Approval Rates [Home page on internet] [cited Jun 15 2021]. Available from: https://blogs.sciencemag.org/pipeline/ archives/2019/05/09/the-latest-on-drug-failure-and-approval-rates.

7. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019; 24(3):773-80. doi:10.1016/j.drudis.2018.11.014, PMID 30472429
8. Sellwood MA, Ahmed M, Segler MHs, Brown N. Artificial intelligence in drug discovery. Future Med Chem. 2018; 10(17):2025-28. doi: 10.4155/fmc-2018- 0212, PMID 30101607.
9. Smith JS, Roitberg AE, Isayev O. Transforming computational drug discovery with machine learning and AI. ACS Med Chem Lett. 2018; 9(11):1065-69.
10. Jing Y, Bian Y, Hu Z, Wang L, Xie XQ. Deep learning for drug design: an artificial intelligence paradigm for drug discovery in the big data era. AAPS J. 2018; 20(3):58. doi: 10.1208/s12248-018-0210-0. PMID 29603063.
11. Powles J, Hodson H. Google DeepMind and healthcare in an age of algorithms. Health Technol (Berl). 2017;7(4):351-67. doi: 10.1007/s12553- 017-0179-1. PMID 29308344.
12. Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011; 23(36):H217-47. doi: 10.1002/adma.201102313, PMID 21842473.
13. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019; 151- 152:169-90. doi: 10.1016/j.addr.2019.05.001, PMID 31071378.
14. Staples M, Daniel K, Cima MJ, and Langer R. Application of micro- and nano- electromechanical devices to drug delivery. Pharm Res. 2006; 23(5):847-63. doi: 10.1007/s11095-006-9906-4, PMID 16715375.
15. Ly DQ. The Matter Compiler—towards atomically precise engineering and manufacture. NtP. 2011; 7(3):199-217. doi: 10.4024/N13LY11A.ntp.07.03.
16. Meziane F, Vadera S, Kobbacy K, Proudlove N. Intelligent systems in manufacturing: current developments and future prospects. Integr Manuf Syst. 2000; 11(4):218-38. doi: 10.1108/09576060010326221.
17. Keshavarzi Arshadi A, Webb J, Salem M, Cruz E, Calad-Thomson S, Ghadirian N, et al. Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development. Front Artif Intell. 2020; 3:65. doi: 10.3389/ frai.2020.00065, PMID 33733182.
18. Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: A discussion of chemical and biological data. Drug Discov Today. 2021; 26(4):1040-52. doi: 10.1016/j. drudis.2020.11.037, PMID 33508423.
19. ENGINEERING S. [Home page on internet] [cited Jun 05 2021]. Available from: https://engineering.stanford.edu/magazine/promise-and-challenges-relying-ai-drug-development
20. Duvenaud DK, Maclaurin D, Iparraguirre J, Bombarell R, Hirzel T, Alan Aspuru-Guzik, et al. Convolutional networks on graphs for learning molecular fingerprints. Adv Neural Inf Process Syst. 2015; 28:2224-32.
21. Duvenaud D, et al. Convolutional networks on graphs for learning molecular fingerprints. The 28th International Conference on Neural Information Processing Systems; 2018.
22. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: toxicity prediction using Deep Learning. Front Environ Sci. 2016; 3:80. doi: 10.3389/ fenvs.2015.00080.
23. DeepTox MA. Toxicity prediction using deep learning. Front Environ Sci. 2016; 3:80.
24. Xu Y, Ma Junshui, Liaw A, Sheridan RP, Svetnik V. Demystifying Multitask Deep Neural Networks for Quantitative Structure-Activity Relationships. J Chem Inf Model. 2017; 57(10):2490-504. doi: 10.1021/acs.jcim.7b00087, PMID 28872869.
25. Sanchez-Lengeling B, Outeiral C, Guimaraes GL, Aspuru-Guzik A. Optimizing distributions over molecular space. An Objective-Reinf Gener Adversarial Network Inverse-Des Chem (Org) ChemRxiv. 2017. doi: 10.26434/chemrxiv.5309668.v3.
26. Ramsundar B, Eastman P, Walters P, Pande V. Deep learning for the life sciences: applying deep learning to genomics, microscopy, drug discovery, and more. 1st ed. O'Reilly Media, Inc; 2019.
27. Riant, F.; Bergametti, F.; Ayrignac, X.; et al. Recent Insights into Cerebral Cavernous Malformations: The Molecular Genetics of CCM. FEBS J. 2010, 277, 1070–1075.
28. Chon, J. Automation and Machine Learning: A Look into Recursion Pharmaceuticals. September 2017. https://www.rarediseasereview.org/publications/2017/9/17/automation-and-machine-learning-a-look-into-recursion-pharmaceuticals
29. Dahl, G. E.; Jaitly, N.; Salakhutdinov, R. Multi-task neural net- works for QSAR predictions. arXiv preprint arXiv:1406.12312014.
30. Mayr, A.; Klambauer, G.; Unterthiner, T.; et al. DeepTox: Toxicity Prediction Using Deep Learning. Front. Environ. Sci. 2016, 3, 80.
31. Ma, J.; Sheridan, R. P.; Liaw, A.; et al. Deep Neural Nets as a Method for Quantitative Structure–Activity Relationships. J. Chem Inform. Model. 2015, 55, 263–274.

32. Xu, K.; Hu, W.; Leskovec, J.; et al. How Powerful Are Graph Neural Networks? arXiv preprint arXiv:1810.00826 2018.
33. Duvenaud, D. K.; Maclaurin, D.; Iparraguirre, J.; et al. Advances in Neural Information Processing Systems. In Convolutional Networks on Graphs for Learning Molecular Fingerprints; Cortes, C., Lawrence, N. D., Lee, D. D., Sugiyama, M., Garnett, R., Eds.; Curran Associates, Inc.: Red Hook, NY, 2015; pp 2224–2232.
34. Glen, R. C.; Bender, A.; Arnby, C. H.; et al. Circular Finger- prints: Flexible Molecular Descriptors with Applications from Physical Chemistry to ADME. IDrugs 2006, 9, 199.
35. Kearnes, S.; McCloskey, K.; Berndl, M.; et al. Molecular Graph Convolutions: Moving beyond Fingerprints. J. Comput. Aid. Mol. Design 2016, 30, 595–608.
36. Schütt, K. T.; Arbabzadah, F.; Chmiela, S.; et al. Quantum- Chemical Insights from Deep Tensor Neural Networks. Nat. Commun. 2017, 8, 1–8.
37. Gilmer, J.; Schoenholz, S. S.; Riley, P. F.; et al. Neural Message Passing for Quantum Chemistry. arXiv preprint arXiv:1704.01212 2017.
38. Liu, K.; Sun, X.; Jia, L.; et al. Chemi-Net: A Molecular Graph Convolutional Network for Accurate Drug Property Prediction. Int. J. Mol. Sci. 2019, 20, 3389.
39. Chan, H. S.; Shan, H.; Dahoun, T.; et al. Advancing Drug Discovery via Artificial Intelligence. Trends Pharmacol. Sci. 2019, 40, 592–604.
40. AlQuraishi, M. AlphaFold at CASP13. Bioinformatics 2019, 35, 4862–4865.
41. Team, A. Computational Predictions of Protein Structures Associated with COVID-19. DeepMind Website K 2020, 417, Y453.
42. Jin, W.; Barzilay, R.; Jaakkola, T. Junction Tree Variational Autoencoder for Molecular Graph Generation. arXiv preprint arXiv:1802.04364 2018.
43. You, J.; Liu, B.; Ying, Z.; et al. Advances in Neural Information Processing Systems. In Graph Convolutional Policy Network for Goal-Directed Molecular Graph Generation; Bengio, S., Wallach, H. M., Larochelle, H., Grauman, K., Cesa-Bianchi, N., Eds.; Curran Associates, Inc: Red Hook, NY, 2018; pp 6410–6421.
44. Shi, C.; Xu, M.; Zhu, Z.; et al. GraphAF: A Flow-Based Autoregressive Model for Molecular Graph Generation. arXiv preprint arXiv:2001.09382 2020.
45. Barratt MJ, Frail DE. Drug repositioning: Bringing new life to shelved assets and existing drugs. John Wiley & Sons 2012. http://dx.doi.org/10.1002/9781118274408
46. Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 2018; 175(2): 168-80.http://dx.doi.org/10.1111/bph.13798 PMID: 28369768
47. Ekins S, Puhl AC, Zorn KM, et al. exploiting machine learning for end-to-end drug discovery and development. Nat Mater 2019; 18(5): 435-41.
48. Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug dis- covery. Drug Discov Today 2017; 22(11): 1680-5.
49. Zhao K, So HC. Using drug expression profiles and machine learning approach for drug repurposing.Computational Methods for Drug Repurposing. New York, NY: Humana Press 2019; pp. 219-37.
50. Park K. A review of computational drug repurposing. Transl Clin Pharmacol 2019; 27(2): 59-63.
51. Koromina M, Pandi MT, Patrinos GP. Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics. OMICS 2019; 23(11): 539-48
52. Zhao K, So HC. A machine learning approach to drug reposition-in based on drug expression profiles: Applications to schizophre- nia and depression/anxiety disorders. arXiv preprint arXiv:170603014 2017.
53. Kim E, Choi AS, Nam H. Drug repositioning of herbal compounds via a machine-learning approach. BMC Bioinformatics 2019;20(10)
54. Yella JK, Yaddanapudi S, Wang Y, Jegga AG. Changing trends in computational drug repositioning. Pharmaceuticals (Basel) 2018; 11(2): 57.